Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also said that he still expected Chinese negotiators to meet with Trump administration officials in Washington in September to continue trade talks.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Gap Inc.'s fiscal second-quarter earnings topped analysts' estimates but sales missed. Same-store sales dropped 4% during the period, worse than expected.Retailread more
Merck reported a bigger-than-expected third-quarter profit on Thursday, driven by higher demand for its blockbuster cancer immunotherapy Keytruda, and the U.S. drugmaker announced a $10 billion share buyback.
The company raised its full-year adjusted earnings forecast, but narrowed its revenue expectation to account for a hit from a stronger dollar.
Sales of Keytruda, which helps the immune system fight cancer, rose 80.4 percent to $1.89 billion from a year earlier and topped estimates of $1.87 billion, according to six analysts polled by Refinitiv.
Merck raised and tightened its full-year adjusted earnings forecast to a range $4.30 to $4.36 per share, from its prior view of $4.22 to $4.30.
The company narrowed its full-year revenue forecast to between $42.1 billion and $42.7 billion. It had previously forecast full-year sales of $42 billion to $42.8 billion.
Merck reported net income of $1.95 billion, or 73 cents per share, in the third quarter ended Sept. 30, compared with a loss of $56 million, or 2 cents per share, a year earlier.
Excluding items, Merck earned $1.19 per share, beating analysts' average estimate of $1.14, according to Refinitiv data.
Revenue rose 4.5 percent to $10.79 billion, but missed Wall Street expectation of $10.88 billion.
Sales of diabetes drug Januvia and related Janumet fell 2.3 percent to $1.49 billion, also missing estimates of about $1.51 billion.